Table 2.
Analyses of NSCLC pooled hazard ratios for OS outcomes by subgroup.
| Variables | Study, N(%) | Number of patients(N) | Pooled HR (95%CI) | p value for interaction | ||
|---|---|---|---|---|---|---|
| LMs | non-LMs | LMs | non-LMs | |||
| Overall | 8 (100) | 1245 | 5614 | 0.78 (0.68,0.90) | 0.72 (0.67,0.78) | 0.24 |
| Therapy line | ||||||
| First-line | 6 (75) | 1002 | 4720 | 0.79 (0.67,0.92) | 0.72 (0.66,0.79) | 0.28 |
| Second- or later-line | 2 (25) | 243 | 894 | 0.77 (0.58,1.02) | 0.71 (0.60,0.84) | 0.63 |
NSCLC, non–small cell lung cancer; LMs, liver metastases; OS, overall survival; HR, hazard ratio; CI, confidence interval.